Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + paclitaxel/carboplatin vs placebo + paclitaxel/carboplatin in Chinese women with FIGO III–IV epithelial ovarian cancer
CTR20180569Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Roche. Started Jul 2018; status: completed.
02
Drugs
bevacizumab
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20180569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180569.